Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Choueiri, Toni K.; Escudier, Bernard; Powles, Thomas; Tannir, Nizar M.; Mainwaring, Paul N.; Rini, Brian I.; Hammers, Hans J.; Donskov, Frede; Roth, Bruce J.; Peltola, Katriina; Lee, Jae‐Lyun; Heng, Daniel Yick Chin; Schmidinger, Manuela; Agarwal, Neeraj; Sternberg, Cora N.; McDermott, David F.; Aftab, Dana T.; Hessel, Colin M.; Scheffold, Christian; Schwab, Gisela; Hutson, Thomas E.; Pal, Sumanta K.; Motzer, Robert J.

doi:10.1016/s1470-2045(16)30107-3

Cited by 836 publications

(808 citation statements)

References 29 publications

Supporting

Mentioning

725

Contrasting

Unclassified

Order By: Relevance

“…Ann Transl Med 2017;5(1):2 atm.amegroups.com advanced RCC who have received a prior antiangiogenic therapy (73,74).…”

Section: Other Tumorsmentioning

confidence: 99%

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy

Pilotto¹,

Gkountakos²,

Carbognin³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Abstract:The MET proto-oncogene plays crucial roles in cell growth and proliferation, survival and apoptosis, epithelial-mesenchymal transition (EMT) and invasion, potentially conditioning the development and progression of the carcinogenesis process. The MET-associated aberrant signaling could be triggered by a variety of mechanisms, such as mutations, gene amplification, increased gene copy number and Met/HGF protein expression. Among the various MET alterations, MET exon 14 splicing abnormalities, causing the loss of the Met juxtamembrane (JM) domain, recently emerged as a new potential oncogenic driver and have been identified and validated across different cancer and histology subtypes. Moreover, this aberration was found to be mutually exclusive with other recognized drivers, thus strongly nominating its potential oncogenic role. Recently, the clinical activity of anti-Met-targeted therapy was demonstrated particularly in patients harboring MET exon 14 skipping lung cancer, resulting in a renewed enthusiasm to further test MET precision therapy in prospective trials. In this review, the key preclinical and clinical data regarding MET exon 14 skipping splicing variants as an actionable genomic aberration in cancer are described, and the perspectives deriving from the validation of such alteration as a potential target, which may further allow driving the therapeutic approach in this molecularly selected patients' subgroup, are explored.

show abstract

“…Ann Transl Med 2017;5(1):2 atm.amegroups.com advanced RCC who have received a prior antiangiogenic therapy (73,74).…”

Section: Other Tumorsmentioning

confidence: 99%

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy

Pilotto¹,

Gkountakos²,

Carbognin³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…Based on article identification and selection, we totally included 28 trials from 35 articles (9-30), involving 17,466 randomly assigned patients ( Figure 1) (31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43).…”

Section: Trial Searching and Characteristicsmentioning

confidence: 99%

Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years

Zhang¹,

Zhang²,

Tang³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

“…58 In the METEOR trial, around 30% of patients had received at least two prior VEGFr TKI therapies with notable benefit in PFS and OS in patients receiving cabozantinib over everolimus.…”

Section: Cabozantinibmentioning

confidence: 99%

“…60 Furthermore, everolimus was found to be inferior to the experimental arm in two large, randomized, phase 3 clinical trials, CHECKMATE 025 and METEOR, where the majority of patients were studied in the second-line setting. 48,58 Given these results, everolimus is likely not the optimal agent of choice for most patients post-initial VEGFr TKI.…”

Section: Everolimusmentioning

confidence: 99%

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017

North

Basappa

Bjarnason

et al. 2017

CUAJ

View full text Add to dashboard Cite

show abstract

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Abstract: Exelixis Inc.

Cited by 836 publications

References 29 publications

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy

Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017

Contact Info

Product

Resources

About